Liang Shan Selected Research

Liang Shan Research Topics

Disease

35	Neoplasms (Cancer) 10/2023 - 09/2002
13	Infections 02/2024 - 11/2009
8	Carcinoma (Carcinomatosis) 04/2005 - 10/2002
7	Hepatocellular Carcinoma (Hepatoma) 01/2024 - 01/2017
6	Fibrosis (Cirrhosis) 01/2024 - 10/2019
6	Squamous Cell Carcinoma of Head and Neck 10/2023 - 01/2008
6	Breast Neoplasms (Breast Cancer) 01/2023 - 09/2002
4	Liver Cirrhosis (Hepatic Cirrhosis) 01/2024 - 03/2020
4	Inflammation (Inflammations) 01/2024 - 02/2015
4	Glioblastoma (Glioblastoma Multiforme) 12/2023 - 01/2015
3	Neoplasm Metastasis (Metastasis) 11/2022 - 01/2008
3	Critical Illness (Critically Ill) 11/2013 - 11/2011
3	Prostatic Neoplasms (Prostate Cancer) 05/2013 - 10/2002
3	Carcinogenesis 07/2004 - 02/2003
2	Bites and Stings (Sting) 03/2024 - 10/2023
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 10/2018
2	Liver Diseases (Liver Disease) 01/2024 - 01/2022
2	Cardiotoxicity 01/2023 - 05/2009
2	HIV Infections (HIV Infection) 01/2023 - 08/2013
2	Hematologic Neoplasms (Hematological Malignancy) 01/2017 - 01/2013
2	Sepsis (Septicemia) 02/2016 - 06/2015
2	Virus Diseases (Viral Diseases) 01/2014 - 06/2013
2	Latent Infection 01/2014 - 03/2012
2	Viremia 03/2012 - 07/2011
2	Adenoma (Adenomas) 01/2005 - 12/2003
1	Disease Progression 02/2024
1	Chronic Hepatitis C 01/2024
1	Fatty Liver 01/2024
1	Diphtheria 10/2023
1	Wounds and Injuries (Trauma) 05/2023
1	Hypothermia 01/2023
1	Nasal Polyps (Nasal Polyp) 01/2023
1	Brain Neoplasms (Brain Tumor) 01/2023
1	Pancreatic Neoplasms (Pancreatic Cancer) 11/2022
1	Body Weight (Weight, Body) 11/2022

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 10/2023 - 12/2003
9	benzocycloheptapyridineIBA 04/2005 - 10/2002
8	CarcinogensIBA 01/2006 - 10/2002
7	2- amino- 1- methyl- 6- phenylimidazo(4,5- b)pyridineIBA 04/2005 - 10/2002
6	InflammasomesIBA 02/2024 - 01/2017
6	Immunotoxins (Immunotoxin)IBA 10/2023 - 01/2013
5	anthraceneIBA 01/2006 - 10/2002
4	Cyclin D1IBA 04/2005 - 10/2002
3	CytokinesIBA 12/2022 - 03/2020
3	ErbB Receptors (EGF Receptor)IBA 03/2022 - 10/2018
3	Diphtheria ToxinIBA 03/2022 - 05/2013
3	MicroRNAs (MicroRNA)IBA 12/2020 - 04/2017
3	huaierIBA 01/2020 - 01/2017
3	Transferrin (beta 2 Transferrin)IBA 11/2010 - 01/2005
3	Proliferating Cell Nuclear Antigen (PCNA)IBA 04/2005 - 02/2003
3	Complementary DNA (cDNA)IBA 02/2005 - 10/2002
2	RNA (Ribonucleic Acid)IBA 03/2024 - 01/2022
2	VaccinesIBA 02/2024 - 10/2017
2	Adenosine (Adenocard)FDA LinkGeneric 01/2024 - 01/2022
2	CollagenIBA 01/2024 - 05/2023
2	Coffee FDA Link 01/2024 - 01/2022
2	Caffeine (No Doz)FDA LinkGeneric 01/2024 - 01/2022
2	muconomycin AIBA 12/2023 - 01/2022
2	Matrix Metalloproteinases (MMPs)IBA 06/2023 - 05/2023
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 06/2015
2	LipopolysaccharidesIBA 01/2023 - 02/2015
2	LuciferasesIBA 11/2022 - 01/2008
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 12/2016
2	AntibodiesIBA 10/2018 - 12/2017
2	Monoclonal AntibodiesIBA 12/2017 - 05/2013
2	tanshinoneIBA 02/2015 - 09/2014
2	Contrast MediaIBA 11/2010 - 03/2007
2	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 02/2005 - 01/2005
2	QuinoxalinesIBA 02/2005 - 01/2005
2	AminesIBA 02/2005 - 07/2004
2	4-biphenylamineIBA 02/2005 - 01/2005
2	Messenger RNA (mRNA)IBA 12/2003 - 02/2003
1	Viral DNAIBA 03/2024
1	DNA (Deoxyribonucleic Acid)IBA 03/2024
1	HIV ProteaseIBA 02/2024
1	FibrinIBA 01/2024
1	EnzymesIBA 01/2024
1	Protective AgentsIBA 01/2024
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2024
1	Interferon Type IIBA 10/2023
1	InterferonsIBA 10/2023
1	Interleukin-15 (Interleukin 15)IBA 10/2023
1	Interleukin-7 (Interleukin 7)IBA 10/2023
1	Interleukin-6 (Interleukin 6)IBA 01/2023
1	Trastuzumab (Herceptin)FDA Link 01/2023
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2022
1	Simvastatin (Zocor)FDA LinkGeneric 11/2022
1	Peptide Hydrolases (Proteases)FDA Link 10/2022
1	Antiviral Agents (Antivirals)IBA 10/2022
1	Pathogen-Associated Molecular Pattern MoleculesIBA 10/2022
1	Pattern Recognition ReceptorsIBA 10/2022
1	Neoplasm Antigens (Tumor Antigens)IBA 03/2022
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 03/2022

Therapy/Procedure

20	Therapeutics 12/2022 - 10/2002
3	Lasers (Laser) 01/2024 - 12/2016
3	Drug Therapy (Chemotherapy) 10/2018 - 02/2012
3	Immunotherapy 12/2017 - 01/2014
3	Highly Active Antiretroviral Therapy (HAART) 06/2013 - 11/2009
2	Tracheotomy 11/2013 - 09/2013
2	Intravenous Administration 01/2008 - 03/2007